New international grants to fuel next-generation malaria vaccines
Empowering regional leaders thorough the Australia Awards Fellowships
Parents and teens prefer conversations over porn-blocking technology
Exploring drug use in older adults: APSAD 2024
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Exploring the Feasibility and Acceptability of Technological Interventions to Pr...
Stellabody®: A novel hexamer-promoting mutation for improved IgG potency
Dynamic nucleolar targeting of dengue virus polymerase NS5 in response to extrac...
20-year trends in Australian methamphetamine-related deaths, 2001-2020.
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing biologic and small molecule therapeutics that have potential application in women's health, infectious disease & immunological conditions.
Find us at BIO 2024 this June.
In collaboration with Monash Institute of Pharmaceutical Sciences (MIPS), we are developing next-gen...
A small molecule therapeutic to potentially combat a variety of conditions affecting women’s sexual ...
A potentially broad spectrum Fc-fusion protein to treat SARS-CoV-2, comprising ACE2 (SARS-CoV-2 rece...
